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ABSTRACT 
The aims of this research are to formulate the management and development of 
intellectual capital and to know the models of intellectual capital that is ideal for 
improving the performance of business and excellence Compete in the global level of 
pharmaceutical industry. This is a qualitative research by using the interpretive 
approach. The techniques of data collection of this research are completed with in depth 
interviews, documentation, and focus group discussion (FGD). The validity of the data 
is done by a test of credibility and transferability test. The technique of data analysis 
used in this research is the data reduction analysis. The results of this research show that 
the formulation of management and development of intellectual capital is create value 
by doing knowledge management knowledge and brain power over; extract value by 
doing innovation management over prototypes of new products or service and maximize 
the value of intellectual property management with over competitive tools. Based on the 
formula of management and development of intellectual capital, it is known that the 
ideal models of management and development of intellectual capital is by using the 
Comprehensive Intellectual Capital Management (CICM).  
  
Keyword: The Model of Management and development, Intellectual capital, Study of 
Interpretive  
                                                                         
PRELIMINARY  
Changes have occurred with the shifting dominance of physical resources to 
intangible resources in the form of knowledge (Andriessen, 2002). The world economy 
today is characterized by the rapid rate of change, globalization and knowledge-based 
products. The emergence of knowledge as a resource that has high competitiveness due 
to knowledge meets the criteria to be developed into a valuable resource for the 
company, rare, difficult or impossible to replicate by competitors and cannot be 
replaced by other resources (Barney, 1991)  
Based on a survey conducted by the Canadian Institute of Chartered Accountants 
(CICA), the top executives of 300 Canadian firms and 500 American corporate finances 
stated that the knowledge resource is a crucial factor for the success of the company 
(IFAC, 1998). The study further states that "know-how" that is owned by the employees 
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will be the most important factor for a company gain a competitive advantage. As well 
as know-how of employees, innovation capabilities, expertise, and the power of thought 
organization will play an important role in defining the company's earning power. Blair 
Margaret, a Brookings Institution economist, who demonstrated that the value of 
knowledge and intangible assets increased significantly since 1982 ( IFAC, 1998). Hard 
assets presented by 62% as the market value of the company in 1982, but then dropped 
to 38% in 1992. In 1995, firms engaged in the health sector gets the value of the book 
market biggest in the world with approximately 75% market value caused by the 
company's intangible assets.  
A large portion of intangible assets on the assets of the organization is supported 
by a major contribution to value creation by firms. Seeing so much intellectual capital 
contribution to value creation of the firm, the company must pay more attention to and 
properly manage its IC that can improve business performance and gain a competitive 
advantage, especially in a global environment. Efforts to improve the performance of 
the company's business in the global era and the knowledgeable should be done by all 
companies including those in pharmaceutical industries. Due to the pharmaceutical 
industry is the manufacturing industry will be a very solid knowledge to the highest 
level of research and innovative compared to other manufacturing industries ( Sharabati 
et al, 2010; Hariyanto, 2010, and Chen et al, 2004). Several studies confirm that 
companies with the allocation of research funding and development (R & D) are large 
and consistent will be the leader in its industry.  
The globalization of the pharmaceutical industry provides a challenge for the 
pharmaceutical industry in Indonesia. Moreover, with the passage of the ASEAN 
harmonization of pharmaceutical regulations creating a single pharmaceutical market in 
ASEAN, providing a competitive landscape of the pharmaceutical industry is more 
complex and more stringent. Pharmaceutical companies in Indonesia are required to 
increase their competitive advantage, at least through the following three things which 
sustain the domestic market, export market development, and build the right strategic 
alliances. Although drug consumption per capita in Indonesia is still the lowest among 
ASEAN countries, but the Indonesian pharmaceutical industry growth rate is in the 
range of 13% -15% per year and is the largest pharmaceutical market potential in 
ASEAN. In 2004 the government began to promote the public health insurance 
programs, which have an impact on the amount of health products spending by 
community continues to increase. In 2009 the Indonesian pharmaceutical market 
reached around IDR 30 trillion, with the structure about 30% of foreign pharmaceutical 
products and domestic pharmaceutical products 70%. (Hariyanto, 2010).  
Thus to be able to compete in the ASEAN region as well as in the global 
environment then the pharmaceutical industry must manage its intellectual capital 
appropriately. Due to based on studies results suggest that intellectual capital has 
significant and positive effects on business performance (Bontis et al, 2000; Bontis, 
1998; Cabrita, et al, 2008; Sharabati et al, 2010; Chen et al, 2004; Belkaoui, 2003), and 
enhance the company's competitive advantage (Chen, 2008).  
Based on the explanation above, the formulation of the problems in this study are 
1. How to manage intellectual capital in order to improve business performance and 
competitive advantage of pharmaceutical companies in Global level, 2. How the 
development of intellectual capital in order to improve business performance and 
competitive advantage of pharmaceutical companies in Global level, 3. How to model 
management and development of intellectual capital development in order to improve 
business performance and competitive advantage of pharmaceutical companies globally. 
Whereas the purposes of this study are 1. To determine the management of intellectual 
capital in order to improve business performance and competitive advantage of 
pharmaceutical companies in Global level, 2. To determine the development of 
intellectual capital in order to improve business performance and competitive advantage 
of pharmaceutical companies in Global level, 3. To find the model management and 
development of intellectual capital development in order to improve business 
performance and competitive advantage of pharmaceutical companies globally. 
   
THEORETICAL OVERVIEW  
Intellectual Capital  
Companies create value from what has been done during the process of knowledge 
creation. Accumulatively, "stock" of knowledge and capability of something "unique" 
for organization learning and experience. Choo and Bontis (2002:16) defines "stock" as 
the company's intellectual capital. Intellectual capital contains different capital rooted 
in employees, organizational routines, intellectual property rights, and relationships with 
customers, suppliers, distributors, and co-workers (Choo and Bontis, 2002).  
Brooking (1997), operationally defines intellectual capital as intellectual materials 
are formalized, acquired, and managed to produce a high-value asset. Not much 
different from that definition, Bontis (1996) revealed that intellectual capital is elusive, 
but once discovered and exploited, it will provide the organization a new resource to 
compete and win. Creation of value and wealth of intellectual capital management 
stated by Stewart (1997) that intellectual capital is intellectual material - knowledge, 
information, intellectual property, experience - that can be used to create wealth. 
Collaboration of brainpower and packaging of useful knowledge.  
According to the Society of Management Accountants of Canada (SMAC) in 
SMAC, 1998, that the balance of the term, intellectual assets is the knowledge-based 
items, the company that will produce a stream of future benefits for the company. These 
include technology, management, and consultation processes, as well as expand the 
intellectual property patents.  
  
Components of Intellectual Capital  
Based on the definition that has been proposed by the researchers and authors of 
intellectual capital, has actually led to the components that exist in intellectual capital. 
Leif Edvinsson for example, states that the value of a company's intellectual capital is 
the amount of human capital and structural capital of those companies (Edvinsson and 
Malone, 1997). Brooking (1996) who states that intellectual capital is a function of four 
types of assets, namely: 1) market assets; 2) intellectual property assets; 3) human-
centered assets; 4) infrastructure assets. Meanwhile, according to IFAC (1998), 
intellectual capital consists of human capital, customer (relational capital), and 
structural (organizational) capital is divided into two groups, namely intellectual 
property and infrastructure assets.  
Meanwhile Marr (2008:2) explains that intellectual capital together physical 
capital and financial capital can be an important resource companies. Intellectual 
capitals included in it are all intangible resources provided to the company and 
contribute to the success of the company's strategy. Intangible resources can be divided 
into three namely human capital, structural capital and human capital.   
 
a.  Human Capital (HC)  
Human Capital specifically presents stock of knowledge embedded in 
individual company capabilities collectively to provide the best solutions from the 
employees (Bontis, 1999, and 2001). Or it could also be expressed as the capabilities 
of all employees in their duties and support in achieving corporate goals. This can 
be interpreted as the number of workers skills, experience, capability, and "tacit 
knowledge" (Edvinsson and Malone, 1997, p 34-5). An example is the capacity of 
innovation, creativity, know how, previous experience, teamwork capacity, 
employee flexibility, tolerance of differences, motivation, employee satisfaction, 
learning capacity, loyalty, education and formal training (CIMA, 2005:2 ). Moon 
and Kym (2006) provide examples that are included in the human capital is part of 
employee capability, employee satisfaction and employee sustainability. 
Sustainability is important because employees associated with employee turnover. 
Companies with high employee sustainability will be easier to achieve corporate 
objectives thus no longer confused with employee turnover. Whereas Chen et al 
(2004) and Sharabati et al (2010) add that employee creativity is also an important 
part of human capital.  
 b.  Structural Capital (SC)  
Structural capital is all non human knowledge in companies such as 
hardware, software, databases, organizational structure, patents, trademarks, and 
everything about the organizational capabilities that support employee productivity. 
Or "everything will be left at the office when employees go home" (Bontis, 
2001:45). Meanwhile (CIMA, 2005:2), defines the structural capital as knowledge 
inside the company. It consists of organizational routines, procedures, systems, 
cultures and databases. For example, organizational flexibility, documentation 
services, the existence of center knowledge, the existence of center knowledge, 
common use of information technology, and organizational learning capacity.  
Structural capital can also be said or same interpreted with Organizational 
Capital (OC). IFAC is one of the parties to equalize between structural capital and 
organizational capital. According to IFAC (1998:9), organizational capital (OC) 
including organizational capabilities are developed to meet the market needs as well 
as patents. Thus any patent, trademark, management tools, improvisation 
techniques, information technology systems, or research and development efforts 
that are implemented or will be implemented to develop the effectiveness and 
profitability of the company can be categorized in organizational (structural) 
capital.  
c.   Relational Capital (RC)  
Relational capital (RC) or customer capital (CC), which includes the 
organization's relationship with external parties such as customer loyalty, goodwill, 
supplier relationships (IFAC, 1998:9), and relations with the public (Moon and 
Kym, 2006). Meanwhile CIMA (2005:2) defines relational capital as the resources 
associated with the company's external relationships - with customers, suppliers, or 
partners in research and development. It is part of the human capital and structural 
capital relating to the company's relationships with stakeholders (investors, 
creditors, customers, suppliers), as well as their perceptions about the company. For 
example are image, customer loyalty, customer satisfaction, relationship with 
suppliers, commercial strength, capacity negotiation with financial entities, and 
environmental activities.  
According to Bontis (1998:67), the main theme of relational capital or 
customer capital is the knowledge of marketing channel and customer relationships. 
Customer capital also present the potential of the organization of intangible assets 
acquired that have passed. Intangible assets include knowledge embedded on related 
customers, suppliers, government, or industry associations. So the essence of 
customer capital is associated with the embedded knowledge of the company's 
external relations.  
 
Development of Intellectual Capital and Business Performance Against 
Competitive Advantage  
Model of the development of intellectual capital is necessary for companies to 
understand and be able to manage it so that it can bring improved performance and the 
company is able to achieve competitive advantage on a global level. This is important 
because the intellectual capitals there are three components that influence each other 
and affect the performance of the human capital, structural capital and relational 
capital. For example, human capital will affect the structural capital and relational 
capital (Chen et al, 2004; Bontis et al 2000; Bontis, 1998). Thus, if known like that then 
there should be special attention and management of the human capital because of the 
dimensions is what affects the other two dimensions. So the company should know and 
understand what the indicators that are part of the human capital are and how to manage 
them. Similarly, structural capital that affect relational capital (Cabrita, et al, 2008), 
then the company must understand the system, the culture, how the organizational 
structure that can improve the performance of relational capital in which there is a 
section that deals with customer. Similarly, the management of relational capital is 
directly related to the customer and the community. How to create the conditions for 
customers who are satisfied with the product or services company, creating customer 
loyalty, how to make a good image in the community, at will it become part of the 
relational capital dimension.  
In addition to relate to performance then it should also be noted that each of the 
dimensions of intellectual capital also affect the company's competitive advantage 
(Chen, 2008). Thus it must be identified ideal dimensions and indicators of intellectual 
capital that can improve performance and global competitive advantage. And after it is 
done modeling the development of intellectual capital that will make it easier for 
companies to manage each component of intellectual capital that will ultimately be able 
to improve performance and achieve competitive advantage globally.  
  
RESEARCH METHODS  
Research Approach  
The second study used a qualitative approach. Qualitative approach in the study of 
intellectual capital is more widely used to formulate and develop policies or 
development of intellectual capital theory itself. As Vandal’s research (2003) that 
makes up the framework for intellectual capital and business community college 
partnership. Similarly, Kok (2007) examines the intellectual capital management for 
higher education institutions. The same thing with a qualitative approach in this study 
will be used to create a model for the management and development of intellectual 
capital that is useful to the pharmaceutical industry improve business performance and 
competitive advantage globally.  
  
Research Object  
Of 240 plants of pharmaceutical industries in Indonesia, which are located in East 
Java province amounted to 47 mills. But of the 47 factories of pharmaceutical industry 
are not all their pharmaceutical headquarters located in the province of East Java. Of the 
47 existing pharmaceutical plants in East Java province, only 44 factories which have a 
head office based in East Java province.  
  
Methods and Data Collection Procedures  
Data collected by in depth interview, documentation and observation.  
a.   In Depth Interview  
In-depth interviews were conducted as part of an approach to qualitative research. In 
depth interviews performed by means of structured interviews and unstructured 
interviews to key informant set before (Moleong, 2000). In depth interviews were 
conducted to understand the business in the pharmaceutical industry, the ins and 
outs and competition of the business in the pharmaceutical industry, and the ideal 
indicators that can improve the performance of the pharmaceutical companies 
achieve competitive advantage and global level.  
b.   Documentation  
Documentation used to collect related data to the performance of the pharmaceutical 
companies for this and other related data. Data can be derived from the primary data 
such as financial reports, prospectus of pharmaceutical companies, as well as 
profiles of Pharmacy GP Indonesia in East Java region. Data can also be derived 
from secondary data such as the level of competition at the level of pharmaceutical 
firms regionally, nationally and internationally, and also the level of productivity of 
the pharmaceutical industry there. This data can be obtained from searching on the 
internet, or from other media.  
c.   Observation  
Observation was done by direct observation to study the object. Observations 
carried out in order to understand the object of research and activity in it. For 
example, marketing activities related to relational capital, as well as activities that 
exist in the personnel department (HRD) is also associated with human capital. 
Similarly, the observations related to systems work, work culture, information 
technology is part of the structural capital. With These observations will 
complement the data in depth interviews and data documentation.  
  
Data Analysis Techniques  
Techniques of data analysis in this research were the domain and taxonomic 
analysis. Domain and taxonomic analyses were used to formulate a model of 
intellectual capital that can improve business performance and achieve competitive 
advantage globally. At this stage will be used either whole data obtained from the 
results of studies conducted with the influence of the quantitative approach of the data 
or in-depth interviews, literature studies, and focus group discussions. Domain analysis 
will be made by the researcher to create a worksheet domain. Next will be made 
taxonomic analysis focused on the exploration stage. Analysis domain and taxonomic 
analyzes carried out simultaneously while data collection in the field.  
 
 
  
ANALYSIS AND DISCUSSION  
Management of Intellectual Capital to Improve Business Performance of the 
Pharmaceutical Industry and Holds Competitive Advantage in Global Level  
a.  Human capital management  
The management of human capital in the context of the pharmaceutical companies is 
more emphasis on the knowledge of employees, employee capabilities, and 
competence of employees. The emphasis of the three is expected that human capital 
management can run well, the beginning of the recruitment, selection processes have 
special specification up to the creation of a special competences possessed by an 
employee. In addition to the specifications in the recruitment of human capital 
management in pharmaceutical companies also consider the staffing system and the 
mandatory training provided to employees (MR initial training, training for new 
employees for production, training of K3(OHS)).  
b. Structural Capital Management  
A structural capital management appropriate to the context of the pharmaceutical 
companies is more emphasis on systems, procedures, working mechanisms, 
organizational processes, and organizational culture are good. With the variety of 
mechanisms had been expected that the condition of the organization or company can 
run well and are always improving the product quality is better than the competitors, 
the better the company's growth, and has a profit or benefit better than rivals or 
competitors. In addition to more emphasis on the circumstances and culture of a 
company's structural capital management in pharmaceutical companies is also more 
emphasis on how a company in this case is the pharmaceutical industry in producing 
products produced in accordance with CPOB.  
c.  Relational capital management  
A relational capital management in accordance with the context of the 
pharmaceutical companies is more emphasis on improving the image of the product, 
consumer or customer satisfaction and increase customer loyalty. Likewise, public 
relations should be improved in order to avoid problems in an enterprise 
environment. With the existence of several mechanisms mentioned above, the 
expected management of relational capital a company can run well, and in 
conjunction with outside parties or marketing associated with the management of 
relational capital is one of the elements of the intellectual capital that must be 
considered good and must be managed well too. Last but not least specific, relational 
capital management in industrial pharmacists also has to maintain a good relationship 
with a health worker or doctor.  
  
Intellectual Capital Development Can Improve Business Performance of 
Pharmaceutical Industry and Achieve Competitive Advantage in Global Level  
Intellectual Capital Development Can Improve Business Performance of 
Pharmaceutical Industry and Achieve Competitive Advantage in Global Level, by 
Comprehensive Intellectual Capital Management (CICM). (Al-Ali, 2003). Efforts to 
manage and develop the IC components can be through the Comprehensive Intellectual 
Capital Management (CICM ). CICM concept consists of three stages, namely 
knowledge management, innovation management, and intellectual property 
management. Each stage has a different purpose. Stages of knowledge management 
aims to create value (value creation), innovation management stage aims issuing value 
(value extraction), and the phases of intellectual property management aims to 
maximize the value (value maximization). 
a.     Development stage IC in Knowledge Management  
1. HC development can be done with improvements in employee recruitment 
process or system of recruitment to be done in the correct manner in accordance 
with the standards of training that should be provided to the employee. HC 
development can also be done with the existing knowledge transfer within the 
company. Knowledge sharing between experienced employees with new 
employees, or between employees senior to junior employees.  
2. Development of SC can do a lean organizational structure optimization in 
strategic decision to be more efficient and effective. Optimizing the development 
of infrastructure, machinery, equipment, and information technology should be 
able to meet the requirements of CPOB.  
3. RC development can be done by always maintaining physician relationships that 
must be continuously improved and are always trying to find new users of other 
health workers.  
b.     Stages of development in the Innovation Management IC  
1. HC development to do is training to grow and develop ideas, creativity, and 
innovation that emerge in new ways, more innovative new work systems, and 
other creative aspects. Therefore, training should be focused on aspects of skill, 
attitude, and knowledge. Knowledge development can be done with the 
knowledge sharing among seniors with junior employees, and between 
experienced employees with new employees. Increase the number and 
competence of pharmacists also be part of the development of HC.  
2. Development of SC that can be done is to develop technologies to optimize it 
owned. Technology or machinery can also be empowered to accept orders from 
other companies, known as maklun products. In addition, the development of 
organizational culture towards an innovative and creative culture, the 
development of research and development department is also important to do.  
3. RC development to do is to use the mass media for optimum imaging products 
and companies. Strengthening marketing team to capture innovation in the 
market for then brought into the company. Development of customer feedback 
for product improvement or innovation. Development through CSR that is 
sustainable for the long term.  
c.     Development stage IC in Intellectual Property Management  
1. HC development must be done on competency-based human resource 
management and career planning system so HC can really give you the best 
work for pharmaceutical companies.  
2. Braindware employee development, especially on the marketing needs to be 
done in order to spearhead sales and marketing is the marketing of 
pharmaceutical companies as well as med rep. Likewise, the development of 
improved pharmacist can in terms of quantity and quality.  
3. SC development can be done by optimizing the role of branded products, 
product leader, and famous off patent products owned by the company. 
Development can be done with the IP portfolio. Another development in the 
SC can be done on information technology, machinery, equipment, and 
systems that have been integrated data base or EDP is also owned by the 
company. Development should also be done on the corporate culture towards a 
professional culture. Likewise, the vision, mission and strategy development 
through various means of evaluation, such as the balanced scorecard.  
4. RC development can be done to maximize the company's reputation to convince 
doctors to ethical products. OTC product development can be done by 
optimizing the role of the mass media, CSR activities. Various co operations 
can be empowered for various corporate interests.  
  
Model of Management and Intellectual Capital Development Can Improve 
Business Performance of Pharmaceutical Industry and Achieve Competitive 
Advantage in Global Level 
Management model and the development of intellectual capital is necessary for 
companies to understand and be able to manage it so that it can bring improved 
performance and the company is able to achieve competitive advantage in the global 
level. This is important because the intellectual capitals there are three components that 
influence each other and affect the performance namely the human capital, structural 
capital and relational capital. For example, human capital will affect the structural 
capital and relational capital (Chen et al, 2004; Bontis et al 2000; Bontis, 1998). Thus, 
models of management and development of intellectual capital in accordance with the 
principles of CICM is like in the picture below  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
Image of Management Model and Intellectual Capital Development Using 
the CICM Model 
  
Based on the image above to note that the CICM model is used to manage the IC 
at every level in every stage of business development and will support the next stage. 
The first phase, which creates value by doing the knowledge management on knowledge 
and brainpower. The first step will support the second step, the extract value with 
innovation management do the prototypes of new products or services. The last or the 
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third step is maximizing the value of intellectual property management on competitive 
tools. Through these three phases is clearly visible division of each stage so hopefully 
there will be no overlapping steps in the management of IC.  
Of the three stages in the CICM if we apply the model to the pharmaceutical 
companies, the first stage, ie, knowledge management is synonymous with the 
pharmaceutical companies of middle level, because when viewed in terms of human 
capital well its resources are still limited human resources, finance and capital, in terms 
of structural capital is still limited to the management of the company is not able to 
perform a variety of innovations and creations in terms of relational capital while also 
still a relationship with your doctor is the  suburban doctor or health worker of lower 
level as a midwife. The use of advertising media as a promotional tool is also not widely 
practiced.  
For the second stage of the Innovation Management is synonymous with the 
pharmaceutical companies that is middle-class level, because when viewed in terms of 
human capital has been training really support creativity and innovation. The result of 
knowledge, skill, and attitude of employees increased so as to develop all existing 
resource companies., In terms of structural capital is do some innovations on the 
development of machinery, equipment, and technology may be caused by the presence 
of CPOB regulations and also from within the company itself. Innovation of the 
company can be done on the basis of a top down approach and bottom up, while in 
terms of relational capital already uses media or marketing campaign that has begun to 
be developed by improving relationships with doctors, change of mindset  from sales 
oriented to marketing oriented already have begun to do for the long-term interests.  
Whereas the last or third stage or is the Intellectual Property Management. At this 
stage pharmaceutical company belonging to the latest category is a mid or  large scale 
pharmaceutical company, because if we look at in terms of human capital in the 
company has been providing planning of competency based human resource 
management and career planning system, in terms of structural capital is doing things 
related to branded products, patent products, and also the products sold in the market or 
required by the terms of the relational capital while there is a good relationship with 
grade A doctor or physician leader has been established. This is certainly very 
beneficial for ethical products of the company because it will be easier to market the 
products of pharmaceutical company has marketing team and team of highly qualified 
sales force. This is related to the way the marketing team to develop relationships with 
physicians and KPDM in hospitals.  
  
CONCLUSION AND SUGGESTIONS  
Conclusion  
1. Intellectual Capital Development Can Improve Business Performance of 
Pharmaceutical Industry and Achieve Competitive Advantage in Global Level, by 
Comprehensive Intellectual Capital Management (CICM). (Al-Ali, 2003). Efforts to 
manage and develop the IC components can be through the Comprehensive 
Intellectual Capital Management (CICM ). CICM concept consists of three stages, 
namely knowledge management, innovation management, and intellectual property 
management. Each stage has a different purpose. Stages of knowledge management 
aims to create value (value creation), innovation management stage aims issuing 
value (value extraction), and the phases of intellectual property management aims to 
maximize the value (value maximization).  
2. Management model and the development of intellectual capital is necessary for 
companies to understand and be able to manage it so that it can bring improved 
performance and the company is able to achieve competitive advantage in the global 
level. This is important because the intellectual capitals there are three components 
that influence each other and affect the performance namely the human capital, 
structural capital and relational capital. For example, human capital will affect the 
structural capital and relational capital.  
3. CICM model is used to manage the IC at every level in every stage of business 
development and will support the next stage. The first phase, which creates value by 
doing the knowledge management  on knowledge and brainpower. The first step will 
support the second step, the extract value by doing innovation management on the 
prototypes of new products or services. The last or the third step, is maximizing the 
value of intellectual property management on competitive tools. Through these three 
phases is clearly visible division of each stage so hopefully there will be no 
overlapping steps in the management of IC.  
  
Suggestion  
a. In relation to the formulation and development of Intellectual Capital management 
can improve business performance and achieve excellence of pharmaceutical 
industry to compete globally then the pharmaceutical companies should pay attention 
to ideal indicators for each component of Intellectual Capital.  
b. For subsequent researchers in relation to research and development to formulate 
Intellectual Capital management can improve business performance and achieve 
excellence of pharmaceutical industry to compete globally should seek alternative 
models other than those actually able to adopt or improve business performance and 
competitive advantage.  
c. Pharmaceutical companies in East Java with respect to research can be a reference in 
the development of the pharmaceutical companies that are members so that 
pharmaceutical companies can improve business performance and achieve 
competitive advantage globally.  
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